INLEXZO
GrowthNDAINTRAVESICALSYSTEMPriority Review
Approved
Sep 2025
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
6/8 — Strong
Priority Review
INLEXZO by Johnson & Johnson is g1/s-phase boundary. Approved for non-muscle invasive bladder cancer (nmibc) with carcinoma in situ (cis) with, without papillary tumors. First approved in 2025.
Drug data last refreshed 12h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INLEXZO is a gemcitabine intravesical system approved by the FDA in September 2025 for direct bladder administration. It functions as a nucleoside metabolic inhibitor that disrupts nucleic acid synthesis to treat bladder cancer. The intravesical route delivers the drug directly to the tumor site, maximizing local concentration while minimizing systemic exposure.
Growth12.0 years to LOE
Early-stage commercial growth phase with J&J backing suggests expanding team investment in market access, field sales, and patient education roles over next 2-3 years.
Mechanism of Action
G1/S-phase boundary. Gemcitabine is metabolized by nucleoside kinases to diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides. Gemcitabine diphosphate inhibits ribonucleotide reductase, an enzyme responsible for catalyzing the reactions that generate deoxynucleoside triphosphates for DNA…
Worked on INLEXZO at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.